News Releases

Latest News

MorphoSys & Novozymes in Slonomics Alliance
Dec 15, 2011
MorphoSys & Novozymes in Slonomics Alliance
MorphoSys & Shionogi Partnership Extension
Nov 03, 2011
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has expanded its current licence agreement with Shionogi & Co., Ltd., Osaka, Japan.
MRI & Roslin Institute Vet Alliance with AbD
Oct 24, 2011
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec business unit entered into an agreement with the Moredun Research Institute and the Roslin Institute at The University of Edinburgh to establish a broad range of research reagents in the veterinary research arena.
Alliance with DFCI for Anti-Infective Research
Jul 25, 2011

“We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area,” commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

7 Diagnostic HuCAL Abs Licensed to Proteomika
May 20, 2011
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that Proteomika S.L., subsidiary of Progenika Group, a Spanish biotechnology company specializing in biomarker discovery, has signed a commercial license agreement for seven diagnostic HuCAL-antibodies from MorphoSys’s AbD Serotec Division.
1 – 5 of 21 Next

Events

University of California San Fran-Mission Bay, CA   February 29, 2012
Oregon Health & Science University Portland, OR  March 14, 2012
View All